Subclinical Hypothyroidism: Treat or Wait?

Subclinical hypothyroidism is one of the most common topics of discussion in the doctor's office today — and one of the most likely to prompt a hasty decision. It isn't a single disease with a single course of action: it's a lab finding that only takes on meaning when you look at the person who received it. After 25 years of caring for thyroid patients, I've learned that the right question is almost never "Is the TSH high?" but rather "High for whom, and since when?" In this article, every claim comes with the scientific reference that supports it — the full list is at the end.

What "subclinical" means, in plain English

The thyroid makes hormone. TSH is the signal the brain sends to it: when hormone runs short, the brain shouts louder, and TSH goes up.

Subclinical hypothyroidism is exactly that situation: TSH is above the reference range, but thyroid hormone is still normal. In other words, the gland is working harder to deliver what's needed — and, for now, it's managing.

The word "subclinical" suggests there are no symptoms, and that's one of the biggest sources of confusion. Plenty of people with this result do have complaints. The term refers to the lab test, not to the experience of the person living in that body.

Why the number alone doesn't decide anything

There's a huge difference between a TSH of 5.5 and a TSH of 14, and treating them as the same thing is the most common mistake.

International guidelines use 10 mIU/L as the dividing line, and not by chance. A large analysis that pooled individual-level data from several population studies showed that the increased cardiovascular risk associated with subclinical hypothyroidism is concentrated in the higher TSH ranges, especially from 10 upward (Rodondi et al., JAMA, 2010).

Below that value lies the gray zone where most patients live — and where the decision calls for context, not reflex.

A slightly high TSH is the beginning of an investigation, not the end of one.

When treatment is a consensus

There are situations where the indication is clear and treatment shouldn't be put off.

• TSH above 10 mIU/L, even without symptoms, according to the European and American guidelines (Pearce et al., European Thyroid Journal, 2013; Jonklaas et al., Thyroid, 2014).
• Pregnant women and women trying to conceive, who follow their own, stricter rules, because the mother's hormone is crucial to the baby's development (Alexander et al., Thyroid, 2017).
• Young patients with symptoms and positive antibodies, in whom the chance of the disease progressing is higher.

What changes when antibodies are positive

This is the piece of information most often missing from the conversation.

The best-known population follow-up study on the subject tracked an entire community for twenty years and showed that the combination of elevated TSH and positive thyroid antibodies predicts progression to overt hypothyroidism much better than either one alone (Vanderpump et al., Clinical Endocrinology, 1995).

Put simply: high TSH with positive antibodies tends to be the start of a disease that's going to take hold. High TSH with negative antibodies is much more likely to be a passing change.

That's why, when TSH is slightly high, checking antibodies once changes the course of action more than repeating the TSH five times.

The honest counterpoint: treatment doesn't always help

Here's the part that rarely shows up in articles arguing that everyone should be treated — and it needs to be spelled out.

The largest clinical trial ever done on the subject randomly assigned patients over 65 with subclinical hypothyroidism to levothyroxine or placebo, without doctors or patients knowing who got what. The result: the medication corrected the lab value, but didn't improve symptoms or fatigue compared with placebo (Stott et al., New England Journal of Medicine, 2017).

A later systematic review that pooled the available trials reached the same conclusion: in the existing studies, treating subclinical hypothyroidism did not produce consistent improvement in quality of life or in thyroid-related symptoms (Feller et al., JAMA, 2018).

And there's a second reason for caution at older ages: TSH naturally rises over the years. An analysis of the US population showed that using a young adult's reference range to evaluate an older person turns an enormous number of people who are simply aging into "patients" (Surks and Hollowell, Journal of Clinical Endocrinology & Metabolism, 2007).

I'm not saying no one should be treated. I'm saying that treating on reflex, looking only at the number, isn't care — it's autopilot.

The risk of overtreatment

Levothyroxine isn't a vitamin. When the dose goes beyond what's needed and TSH drops too low, there's a price.

A large population-based study followed patients on long-term levothyroxine and found that those with suppressed TSH had more cardiovascular events, more arrhythmias, and more fractures than those with TSH within the range (Flynn et al., Journal of Clinical Endocrinology & Metabolism, 2010).

In other words: overtreatment has measurable consequences, especially for the heart and bones. That's not an argument against treating those who need it — it's an argument for getting the dose right and reassessing.

The practical mistake that ruins everything

If you take away just one thing from this article, let it be this:

You don't decide to start a lifelong medication based on a single lab result.

There are two solid reasons for this.

The first is that TSH fluctuates. Each person has a very narrow individual range, while the lab's reference range is wide because it has to cover everyone (Andersen et al., Journal of Clinical Endocrinology & Metabolism, 2002). A single result that falls outside the range doesn't necessarily describe how your body usually works.

The second is that a significant share of these results go back to normal on their own. A five-year follow-up in a large primary care network showed that many mildly elevated TSH results returned to normal without any treatment (Meyerovitch et al., Archives of Internal Medicine, 2007).

Acute illness, a recent infection, certain medications, and even the time of day the blood is drawn can all affect the result.

So what should you do?

1. Repeat the TSH along with free T4 in a few weeks, away from any acute illness.
2. Check anti-TPO antibodies once, to find out whether there's autoimmunity behind it.
3. Take age into account: what's concerning at 30 doesn't carry the same weight at 80.
4. Take symptoms seriously, without automatically blaming all of them on the thyroid.
5. If treatment is started, reassess in a few weeks and adjust — and have the courage to stop it if it brought no benefit at all.

The bottom line

Subclinical hypothyroidism doesn't automatically mean disease, and it doesn't automatically mean nothing. It's a sign that the thyroid is working under strain, and what to do depends on how much strain, for what reason, and in whom.

Treating everyone is overkill. Ignoring everyone is neglect. The work lies in telling one case from the other — and that takes more than one visit and more than one lab test.

If you got a result like this and walked out with a prescription the same day, without anyone repeating the test, checking your antibodies, or asking how you've been feeling, it's worth having a second conversation. Not because the treatment is necessarily wrong, but because the decision deserved more than a number.

Scientific references

• Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. New England Journal of Medicine. 2017;376(26):2534-2544. PMID: 28402245.
• Feller M, Snel M, Moutzouri E, et al. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. JAMA. 2018;320(13):1349-1359. PMID: 30285179.
• Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365-1374. PMID: 20858880.
• Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA guideline: management of subclinical hypothyroidism. European Thyroid Journal. 2013;2(4):215-228. PMID: 24783053.
• Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751. PMID: 25266247.
• Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315-389. PMID: 28056690.
• Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clinical Endocrinology. 1995;43(1):55-68. PMID: 7641412.
• Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. Journal of Clinical Endocrinology & Metabolism. 2007;92(12):4575-4582. PMID: 17911171.
• Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. Journal of Clinical Endocrinology & Metabolism. 2010;95(1):186-193. PMID: 19906785.
• Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T4 and T3 in normal subjects: a clue to the understanding of subclinical thyroid disease. Journal of Clinical Endocrinology & Metabolism. 2002;87(3):1068-1072. PMID: 11889165.
• Meyerovitch J, Rotman-Pikielny P, Sherf M, et al. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Archives of Internal Medicine. 2007;167(14):1533-1538. PMID: 17646608.